BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced plans to expand its influenza vaccine development initiative following favorable research outcomes related to the Company’s ‘PBS-1’ cell line. HepaLife’s patented PBS-1 cell line is being developed for application in novel, cell-culture-based vaccine production to help protect against the spread of influenza viruses among humans, including potentially the high-pathogenicity H5N1 avian flu virus.
